3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Tumor Lysis Syndrome
2
Lymphoma
1
Leukemia
1
Inflammation
1
Hyperuricemia
1
Hematologic Neoplasms
1
Gout
1
Cardiovascular Diseases
1
Arthritis
1
Interventions
Cytarabine
21
Imatinib Mesylate
20
venetoclax
16
Azacitidine
16
nilotinib
15
Cyclophosphamide
15
fludarabine
13
Dasatinib
12
blinatumomab
10
Rituximab
10
quizartinib
7
Gemtuzumab
7
Daunorubicin
7
ruxolitinib
6
Drug Therapy
6
Clofarabine
6
Bendamustine Hydrochloride
6
AP 1903 reagent
6
ponatinib
5
fludarabine phosphate
5
Whole-Body Irradiation
5
Vincristine
5
Mycophenolic Acid
5
Methotrexate
5
Granulocyte Colony-Stimulating Factor
5
Dexamethasone
5
vosaroxin
4
revumenib
4
rasburicase
4
forodesine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia
×
Febuxostat
×
Clear all
NCT01724528
2014-11-03
FLORENCE
Menarini Group
Phase 3
Completed
346 enrolled
16 charts